Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Respiratory

PUBLISHER: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | PRODUCT CODE: 1514250

Cover Image

PUBLISHER: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | PRODUCT CODE: 1514250

Chronic Obstructive Pulmonary Disease (COPD) Treatment

PUBLISHED:
PAGES: 299 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF & Excel (Single User License)
USD 5850
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market to Reach US$27.8 Billion by 2030

The global market for Chronic Obstructive Pulmonary Disease (COPD) Treatment estimated at US$20.4 Billion in the year 2023, is expected to reach US$27.8 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2023-2030. Combination Drugs, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$15.9 Billion by the end of the analysis period. Growth in the Bronchodilators Drugs segment is estimated at 4.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.5 Billion While China is Forecast to Grow at 7.6% CAGR

The Chronic Obstructive Pulmonary Disease (COPD) Treatment market in the U.S. is estimated at US$5.5 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$5.9 Billion by the year 2030 trailing a CAGR of 7.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.3% and 3.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.0% CAGR.

Chronic Obstructive Pulmonary Disease (COPD) Treatment  - Key Trends and Drivers

Chronic Obstructive Pulmonary Disease (COPD) is a progressive and debilitating respiratory condition characterized by airflow obstruction, making it difficult for patients to breathe. The disease encompasses two main conditions: chronic bronchitis, which involves long-term inflammation of the airways, and emphysema, where the air sacs in the lungs are damaged. COPD is primarily caused by long-term exposure to harmful irritants, most commonly cigarette smoke, but also environmental pollutants and occupational dust and chemicals. Symptoms include chronic cough, mucus production, shortness of breath, and frequent respiratory infections. COPD significantly impacts patients' quality of life and can lead to severe complications, including respiratory failure. Early diagnosis and effective management are crucial in slowing disease progression and improving patient outcomes.

The treatment landscape for COPD has evolved significantly over the years, with a focus on improving symptoms, enhancing lung function, and preventing exacerbations. Pharmacological treatments are the cornerstone of COPD management and include bronchodilators, corticosteroids, and combination inhalers. These medications help to relax the muscles around the airways, reduce inflammation, and improve airflow. In addition to these, newer therapies such as phosphodiesterase-4 inhibitors and monoclonal antibodies are being explored for their potential to target specific pathways involved in COPD pathology. Non-pharmacological treatments, such as pulmonary rehabilitation, oxygen therapy, and lifestyle modifications, are also critical components of a comprehensive COPD management plan. Pulmonary rehabilitation programs, which combine exercise training, nutritional advice, and education, have shown significant benefits in enhancing patients' physical and emotional well-being.

The growth in the COPD treatment market is driven by several factors. Advances in medical technology, particularly in inhaler design and drug delivery systems, are enhancing the efficacy and convenience of treatments, thereby driving adoption. The increasing prevalence of COPD, partly due to aging populations and continued exposure to risk factors, is expanding the addressable patient population. Furthermore, heightened awareness and early diagnosis of COPD are resulting in more patients receiving timely and effective treatments. Pharmaceutical companies are investing heavily in research and development to discover novel therapies and improve existing treatments, generating new opportunities in the market. The shift towards personalized medicine, where treatments are tailored to individual patient profiles, is also spurring growth by optimizing therapeutic outcomes. Additionally, the rise in telemedicine and remote monitoring technologies is facilitating better management of COPD, allowing for timely interventions and continuous care. These factors collectively are propelling the growth of the COPD treatment market, ensuring better management and improved quality of life for patients worldwide.

Select Competitors (Total 53 Featured) -

  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Chiesi Farmaceutici SpA
  • GlaxoSmithKline PLC
  • Mylan NV
  • Novartis International AG
  • Orion Corporation
  • Sunovion Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Ltd.
Show more
Product Code: MCP-6220

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Chronic Obstructive Pulmonary Disease (COPD) Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advances in Inhaler Technology Propel Growth in COPD Treatment Market
    • Increasing Prevalence of COPD Expands Addressable Market Opportunity
    • Aging Population Spurs Demand for COPD Treatments
    • Enhanced Drug Delivery Systems Drive Adoption of COPD Therapies
    • Rise in Telemedicine and Remote Monitoring Generates New Market Opportunities
    • Early Diagnosis of COPD Accelerates Demand for Effective Treatments
    • Pharmaceutical Innovations in Bronchodilators and Corticosteroids Propel Market Growth
    • Integration of AI and Machine Learning in COPD Management Expands Market Reach
    • Development of Combination Therapies Generates Increased Market Demand
    • Adoption of Pulmonary Rehabilitation Programs Spurs Growth in COPD Treatment Market
    • Technological Innovations in Monoclonal Antibodies Create New Opportunities
    • Improved Diagnostic Tools Drive Early Detection and Treatment of COPD
    • Expansion of Healthcare Infrastructure in Emerging Markets Expands Addressable Market
    • Focus on Non-Pharmacological Treatments Enhances Comprehensive COPD Management
    • Growth in Home Healthcare Solutions Strengthens Business Case for COPD Treatments
    • Consumer Preference for Less Invasive Treatments Drives Demand for New COPD Therapies
    • Advancements in Genetic Research Propel Growth in Personalized COPD Treatments
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Combination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Bronchodilators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Bronchodilators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Bronchodilators by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Phosphodiesterase Type 4 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Phosphodiesterase Type 4 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Phosphodiesterase Type 4 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Mucokinetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Mucokinetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Mucokinetics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • JAPAN
    • Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • CHINA
    • Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 32: China Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: China Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: China 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • EUROPE
    • Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 35: Europe Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Europe 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Europe Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Europe 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • FRANCE
    • Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 41: France Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: France Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: France 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • GERMANY
    • Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 44: Germany Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Germany Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Germany 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 47: Italy Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Italy Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Italy 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 50: UK Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: UK Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: UK 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 53: Spain Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Spain Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Spain 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 56: Russia Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Russia Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Russia 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 59: Rest of Europe Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Rest of Europe Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Rest of Europe 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 63: Asia-Pacific Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Asia-Pacific 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 65: Asia-Pacific Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Asia-Pacific Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Asia-Pacific 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 68: Australia Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Australia Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Australia 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • INDIA
    • Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 71: India Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: India Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: India 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 74: South Korea Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: South Korea Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: South Korea 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 77: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Rest of Asia-Pacific Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Rest of Asia-Pacific 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 80: Latin America Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 81: Latin America Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Latin America 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 83: Latin America Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Latin America Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Latin America 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 86: Argentina Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Argentina Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Argentina 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 89: Brazil Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Brazil Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Brazil 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 92: Mexico Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Mexico Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Mexico 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 95: Rest of Latin America Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Latin America Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Latin America 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 98: Middle East Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 99: Middle East Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Middle East 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 101: Middle East Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Middle East Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Middle East 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 104: Iran Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Iran Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Iran 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 107: Israel Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Israel Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Israel 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 110: Saudi Arabia Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Saudi Arabia Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Saudi Arabia 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 113: UAE Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UAE Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: UAE 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 116: Rest of Middle East Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Rest of Middle East Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Rest of Middle East 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030
  • AFRICA
    • Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 119: Africa Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Africa Historic Review for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Africa 16-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Treatment by Drug Class - Percentage Breakdown of Value Sales for Combination, Bronchodilators, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids and Other Drug Classes for the Years 2014, 2024 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!